Subsidiary of Shandong Xinhua Pharmaceutical (000756.SZ) obtains registration certificate for Finasteride tablets.

Shandong Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (referred to as "Xinda Pharmaceutical") has received the Drug Registration Certificate for Finasteride Tablets issued by the National Medical Products Administration. Finasteride tablets are used to treat and control benign prostatic hyperplasia (BPH) and prevent urinary system events: reducing the risk of acute urinary retention; reducing the risk of needing transurethral resection of the prostate (TURP) and prostatectomy. Finasteride tablets can shrink the enlarged prostate, improve urine flow, and improve symptoms related to prostate hyperplasia.